176 related articles for article (PubMed ID: 29668614)
1. Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report.
Wang LX; Chen X; Jia M; Wang S; Shen J
Medicine (Baltimore); 2018 Apr; 97(16):e0455. PubMed ID: 29668614
[TBL] [Abstract][Full Text] [Related]
2. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
3. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
4. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
Chen HH; Kuo CY; Ho CL; Chen YC
Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
[TBL] [Abstract][Full Text] [Related]
5. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Ahmad A; Uddin S; Steinhoff M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
[TBL] [Abstract][Full Text] [Related]
6. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
8. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
9. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of Chimeric Antigen Receptor T Cell in the Treatment of Refractory/Recurrent B Acute Lymphocytic Leukemia in Children].
Yang F; Wang TY; DU WW; He HL; Xiao PF; Lu Y; Hu SY; Li BS; Lu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):718-725. PubMed ID: 35680795
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
Frey NV; Shaw PA; Hexner EO; Pequignot E; Gill S; Luger SM; Mangan JK; Loren AW; Perl AE; Maude SL; Grupp SA; Shah NN; Gilmore J; Lacey SF; Melenhorst JJ; Levine BL; June CH; Porter DL
J Clin Oncol; 2020 Feb; 38(5):415-422. PubMed ID: 31815579
[TBL] [Abstract][Full Text] [Related]
12. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
13. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
14. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.
Davis JA; Gaffney KJ; McGann M; Smith D; Edwards K; Baldino E; Bakos K; Butcher C; Greenwell B; Hess BT; Hashmi H
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e14-e18. PubMed ID: 36319568
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
Xie L; Ma L; Liu S; Chang L; Wen F
Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
[TBL] [Abstract][Full Text] [Related]
16. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
Zhou LL; Ye SG; Li P; Tang XC; Liang AB
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
[No Abstract] [Full Text] [Related]
17. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Stolz S; Roncador M; Rösler W; Zenz T; Manz MG; Müller AMS; Widmer CC
Swiss Med Wkly; 2022 Jun; 152():w30186. PubMed ID: 35752964
[TBL] [Abstract][Full Text] [Related]
18. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
[TBL] [Abstract][Full Text] [Related]
19. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
Front Immunol; 2021; 12():707191. PubMed ID: 34349766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
